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Abstract
Introduction: Radioligand imaging is a powerful in vivo method to assess the molecular basis of Alzheimer’s
Disease. We therefore aimed to visualize the pathological deposition of fibrillar amyloid-β and neuronal dysfunction
in aged double transgenic mice.
Methods: Using non-invasive positron emission tomography (PET) we assessed brain glucose utilization with
[18F]FDG and fibrillar amyloidosis with [11C]PiB and [18F]AV45 in 12 month old APPPS1-21 (n = 10) mice and their
age-matched wild-type controls (n = 15). PET scans were analyzed with statistical parametric mapping (SPM) to
detect significant differences in tracer uptake between genotypes. After imaging, mice were sacrificed and ex vivo
measures of amyloid-β burden with immunohistochemistry as well as glucose utilization with [14C]-2DG
autoradiography were obtained as gold standards.
Results: Voxel-wise SPM analysis revealed significantly decreased [18F]FDG uptake in aged APPPS1-21 mice in
comparison to WT with the thalamus (96.96 %, maxT = 3.35) and striatum (61.21 %, maxT = 3.29) demonstrating the
most widespread reductions at the threshold of p < 0.01. [11C]PiB binding was significantly increased in APPPS1-21
mice, most notably in the hippocampus (87.84 %, maxT = 7.15) and cortex (69.08 %, maxT = 7.95), as detected by
SPM voxel-wise analysis at the threshold of p < 0.01. Using the same threshold [18F]AV45 uptake was comparably
lower with less significant differences. Compared to their respective ex vivo equivalents [18F]FDG demonstrated
significant positive correlation to [14C]2-DG autoradiography (r = 0.67, p <0.0001) while [11C]PiB and [18F]AV45
binding did not correlate to ex vivo immunohistochemistry for amyloid-β (r = 0.25, p = 0.07 and r = 0.17, p = 0.26
respectively). Lastly no correlation was observed between regions of high amyloid burden and those with
decreased glucose utilization (r = 0.001, p = 0.99).
Conclusions: Our findings support that fibrillar amyloid-β deposition and reduced glucose utilization can be
visualized and quantified with in vivo μPET imaging in aged APPPS1-21 mice. Therefore, the combined use of
[18F]FDG and amyloid μPET imaging can shed light on the underlying relationship between fibrillar amyloid-β
pathology and neuronal dysfunction.
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Introduction
Nuclear medicine imaging of the human brain afflicted
by Alzheimer’s Disease (AD) has progressed over the last
decades from non-specific markers of neurodegenera-
tion, such as altered metabolism [1, 2], blood flow [3],
and inflammation [4, 5], to disease-specific markers of
amyloid-β [6] and tau tangles [7] believed to instigate
the pathologic cascade. For diagnostic purposes, the
functional metabolic marker [18F]fluorodeoxyglucose
([18F]FDG) remains the most routinely used positron
emission tomography (PET) radioligand [8] but the
more novel amyloid-β tracers are increasingly used since
their recent clinical approval (Amyvid, Neuraceq, and
Vizamyl) and growing availability. In clinical studies the
combined use of these tracers allows the non-invasive
tracking of AD from the early pathologic events of
amyloid-β deposition to the later neurodegenerative
mechanisms related to clinical decline and have proved
seminal in understanding the natural history of AD.
Given the clinical utility of [18F]FDG and amyloid
tracers, there is considerable interest in back-translating
their success to preclinical investigations. A number of
transgenic mouse models of cerebral amyloidosis are
readily available and are generally created by the ma-
nipulation of the genes involved in amyloid processing
[9]. While investigation of these models has led to a
greater understanding of amyloid-related disease mecha-
nisms, they are limited by the primary use of ex vivo
methods to assess brain pathology. The application of
small animal PET imaging (μPET) to preclinical research
allows for the simultaneous longitudinal monitoring of a
number of physiological processes in a subject over time
and can thus enhance the translational value of animal
studies. Despite having lower affinity for fibrillar amyloid-
β in animal models [10, 11], amyloid tracers have success-
fully monitored progressive amyloidosis in a number of
transgenic cerebral amyloidosis models [11–17] and have
been shown sensitive enough to detect treatment-induced
reductions in plaque load with an anti-amyloid antibody
[11] and a γ-secretase inhibitor [18]. Although [18F]FDG
is a better-established tracer, its ability to detect cerebral
hypometabolism in amyloidosis models with μPET is de-
bated. Early investigations of glucose utilization in trans-
genic models with [18F]FDG focused on the high-
resolution technique of ex vivo autoradiography. With this
method a number of models were shown to have reduc-
tions in [18F]FDG uptake in brain regions with homology
to those affected in clinical AD [19–23]. However when
applied in vivo with μPET scanners the majority of studies
have reported either unchanged [24, 25] or increased
[18F]FDG [26–28] uptake in transgenic models. Given the
lower resolution of μPET in comparison to autoradiog-
raphy, decreased sensitivity may indeed mask small re-
gional decreases in [18F]FDG uptake between genotypes
[29]. However these discrepancies may also be accounted
for by methodological factors [30] in addition to strain dif-
ferences. More recently in vivo hypometabolism in amyl-
oidosis models has been described [31–33].
The assessment of glucose utilization is a necessary
adjunct to amyloid imaging to unravel the relationship
between amyloid-β and neuronal dysfunction. While
amyloid imaging may provide a read-out of target en-
gagement for amyloid targeted therapies, such therapies
should also be tested for their ability to prevent loss of
neuronal function. Moreover, monitoring therapeutic ef-
ficacy with [18F]FDG would provide a valuable in vivo
biomarker for non-amyloid targeted therapies, such as
neuroprotective strategies or symptomatic relief. We
have previously investigated the use of [18F]FDG and the
amyloid tracer [18F]florbetapir in the double transgenic
TASTPM mouse model and demonstrated significantly
increased retention of [18F]florbetapir and significantly
lower [18F]FDG uptake in these aged animals [33]. We
aimed here to extend our findings using a different
double transgenic model of amyloidosis and confirming
our in vivo findings with ex vivo [14C]2-DG autoradiog-
raphy. We chose to investigate APPPS1-21 mice as they
have demonstrated synaptic alterations [34, 35] and cog-
nitive impairment [36, 37] and, thus, represent an inter-
esting model for measuring neuronal dysfunction. We
additionally utilized [11C]PiB and [18F]AV45 binding [38]




We employed APPPS1-21 (n = 10) double transgenic
mice that co-express the human Swedish double APP
mutation KM670/671NL and the human mutated PS1
L166P driven by the neuron-specific Thy-1 promoter
element. Due to these mutations APPPS1-21 mice
undergo accelerated and severe disease pathogenesis.
Amyloid-β deposition begins as early as six weeks of age
and at later stages these mice have extensive dense core
plaque pathology [36]. Wild-type littermates (WT) were
used as controls (C57BL6J, n = 15) and all animals were
female. The animals were kept under environmentally
controlled conditions (12 h light/dark cycle, 20–24 °C
and 40–70 % relative humidity) in individually ventilated
cages with food and water ad libitum. Animals were
group-housed and received environmental enrichment.
Mice were 12 months old at the time of imaging. The
study protocol was approved by the local Animal Experi-
mental Ethical Committee of the University of Antwerp,
Belgium (2012–25) where the in vivo experiments were
performed. All animal studies were ethically reviewed
and carried out in accordance with European Directive
86/609/EEC Welfare and Treatment of Animals.
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Tracer radiosynthesis
[11C]PiB was synthesized according to the one step
method under neutral conditions as described previously
[38]. [18F]FDG was prepared using a cassette based GE
Fastlab synthesis module (GE Healthcare, Diegem,
Belgium). [18F]-AV45 was synthesized from the tosyloxy
precursor AV-105 by modification of the method as de-
scribed by Yao and coworkers [39].
PET image acquisition and analysis
Static μPET scans (Siemens Preclinical Solution, Knoxville,
TN, USA) were acquired after intravenous tracer injection
and a conscious uptake period. For [18F]FDG, mice re-
ceived 18.65 ± 0.62 MBq (45 min uptake, 20 min scan).
Prior to scanning, animals were fasted overnight for 8–12
hours and blood glucose levels were monitored by a diag-
nostic assay. For [11C]PiB, mice received 4.28 ± 1.06 MBq
(20 min uptake, 30 min scan) while for [18F]AV45 mice re-
ceived 17.8 ± 0.92 MBq (30 min uptake, 20 min scan).
Anesthesia was induced by inhalation of isoflurane (5 %
for induction, and 2 % for maintenance during prepar-
ation and scanning) supplemented with oxygen. The
core body temperature of the animals was maintained
via a temperature controlled heating pad.
μPET data was reconstructed with two-dimensional
ordered subsets expectation maximization (OSEM2D)
[40] algorithm using four subsets and 16 iterations fol-
lowing Fourier rebinning (FORE) [41]. The energy and
timing window was set to 350–650 keV and 3.432 nsec,
respectively. The μPET images were reconstructed on a
128 x 128 x 159 grid with a pixel size of 0.776 mm and a
slice thickness of 0.796 mm. Normalization, dead time,
randoms, CT-based attenuation and single scatter simu-
lation (SSS) [42] corrections were applied. A five min
CT was acquired subsequent to all PET scans using a
220 degree rotation with 12- rotation steps; voltage and
amperage were set to 80 keV and 500 uA, respectively.
Volume-of-interest (VOI) and voxel-wise analysis (stat-
istical parametric mapping) methods were performed on
reconstructed images using PMOD v3.3 (PMOD tech-
nologies, Zurich, Switzerland) and SPM8 (Wellcome Trust
Centre, London, UK). Individual PET images were
spatially normalized into the space of a predefined mouse
brain template [43] by matching the individual animal
specific CT to the template CT and applying the same
transform to the PET which is by default matched to its
CT via the PET/CT scanner hardware. Thereafter, extra-
cerebral activity was removed through the use of a brain
mask derived from the Mirrione T2 -weighted MR tem-
plate (a priori matched with the same CT template) [43]
whereby all voxels outside the brain mask were set to zero
intensity and voxels inside the mask were unaltered. For
an absolute measure of tracer uptake, normalized images
were scaled according to the percent injected dose for
[11C]PiB and [18F]AV45 (tissue uptake[kBq/cc]/injected
dose[kBq] * 100) and glucose-corrected percent
injected dose for [18F]-FDG (tissue uptake[kBq/cc] *
blood glucose/injected dose[kBq] *100).
For VOI analysis, processed images were subsequently
co-registered with a predefined mouse brain VOI tem-
plate (encompassing all relevant brain regions) aligned
with the aforementioned Mirrione CT/MRI atlas and
tracer uptake values were extracted for each delineated
VOI. With this approach regional values are quantified
as the average uptake over the total number of voxels in
a VOI.
For voxel-wise analysis of tracer uptake between ge-
notypes, a two-sample unpaired t-test was applied to
normalized and scaled images, with a significance
threshold of p < 0.01 for all tracers with an extent
threshold of 100 voxels (48 mm3), uncorrected for
multiple comparisons. Quantification of this voxel-
wise analysis was investigated by employing two indi-
ces: 1) the number of significant voxels in a VOI rela-
tive to the total number of voxels (% sign); and 2) the
maximal T value (maxT). For qualitative purposes T-maps
were smoothed with an isotropic Gaussian kernel with
0.5 mm full width at half maximum (FWHM) subsequent
to analysis.
Ex vivo gold standard evaluation
Mice were 13 months old (end of life). Mice were fasted
for 12 hr to stabilize plasma glucose levels prior to an
intraperitoneal injection of 0.148 MBq (weight adjusted)
[14C]2-DG. After a conscious uptake period of 45 min,
mice were sacrificed by decapitation and the brains rapidly
removed. After decapitation plasma glucose was measured
by a diagnostic assay.
For autoradiography, the left brain hemisphere was
frozen in cooled 2-methylbutane (−30 °C on dry ice) for
approximately one min. This hemisphere was then cov-
ered in tissue embedding medium which was allowed to
cool to −20 °C. Coronal sections (20 μm thick) were
sliced in triplicate by a cryostat and thaw mounted on
glass microscope slides. The slides were immediately
placed on a heating plate (60 °C) for five to ten min to
prevent diffusion of [14C]2-DG out of the cells. These
slices were co-exposed with a commercially available
[14C] standard to autoradiography film for four days.
After the exposure time, the autoradiograms were devel-
oped in a dark room. The autoradiograms were quanti-
fied with MCID Basic 7.0 (Imaging Research Inc.,
St.Catherine's, ON, Canada) image analyzer software.
Relative optical densities (ROD) were transformed into
levels of bound radioactivity (dpm/mg tissue-equivalent)
after calibration using the co-exposed [14C]-standard.
Regions of interest were then outlined manually with
reference to the stereotaxic atlas of Paxinos and Franklin
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[44]. The cortex was analyzed at three levels: frontal, the
level of the striatum, and the level of the hippocam-
pus. Other regions investigated were the cerebellum,
thalamus, striatum, hippocampus, and amygdala.
For immunohistochemistry, the right brain hemisphere
was fixed, paraffin-embedded and cut into 5 μm coronal
sections. For immunohistochemistry sections were de-
waxed with xylene and rehydrated by submerging in a
graded series of ethanol with decreasing concentrations.
Sections to be stained for amyloid-β underwent the fol-
lowing pre-treatment steps. First sections were bleached
with potassium permanganate (three min), rinsed in
water (one min), decolorized in oxalic acid (one min),
and rinsed again (one min). Thereafter, antigen retrieval
was performed at room temperature by immersion in
formic acid (ten min). Sections to be stained for reactive
gliosis and neuronal loss underwent heat-mediated
antigen retrieval by microwaving in citrate buffer
(pH 6, ten min). For all sections endogenous peroxid-
ase activity was quenched by rinsing in peroxidase
blocking solution (DAKO S2023, Glostrup, Denmark)
five min). Sections were then incubated with the ap-
propriate primary antibody at room temperature
(60 min). For detection of amyloid-β the primary anti-
body clone 4G8 (Eurogentec SIG-39200, 1/20, 000, Fre-
mont, CA, USA) was used. Reactive gliosis was detected
with anti- glial fibrillary acidic protein (GFAP) (Calbio-
chem IF03L, 1/500, San Diego, CA, USA) and anti-Iba-1
(Wako 019–19741, 1/500 dilution, Richmond, VA, USA)
primary antibodies. Following incubation with the respect-
ive primary antibody, sections were thoroughly rinsed in
wash buffer and subsequently incubated in peroxidase
coupled secondary antibody (30 min) (DAKO K4001,
DAKO K4002). After, sections were washed in buffer
and immunodetection was performed by treatment
with the chromogenic 3–3 diaminobenzidine (DAB)
solution. Finally sections were counterstained with
hematoxylin, dehydrated by submerging in a series of
ethanol, fixed in xylene, mounted and coverslipped.
For sections stained for amyloid-β, virtual images were
acquired using a Mirax Digital Slide Scanner (Carl Zeiss,
Germany) and image analysis was performed using the
Definiens analysis software package v1.5. For all other
stainings, slides were scanned with a NanoZoomer slide
scanner (Hamamatsu Photonics, Shizuoka, Japan) and
analyzed with Matlab/Phaedra. In each case, regions-
of-interest (ROIs) were manually delineated in accord-
ance with Franklin and Paxinos atlas [44] and for each
ROI the percentage of DAB-labeled area was
calculated.
Statistical analysis
Statistical analysis was performed with GraphPad Prism
v6 software.
Results
In vivo μPET imaging
[18F]FDG
VOI analysis (Fig. 1a) demonstrated a trend of reduced
[18F]FDG uptake in APPPS1-21 mice that reached
significance in the thalamus (p = 0.00068) and stri-
atum (p = 0.0048). We additionally employed voxel-
wise analysis (threshold p < 0.01, extent threshold
100 voxels) to investigate whether APPPS1-21 mice
had either increased or decreased [18F]FDG uptake
in comparison to age-matched WT.
Using two-sample t-tests no voxels were shown to
have significantly increased uptake in APPPS1-21 (add-
itionally at the lower threshold of p < 0.05). On the other
hand, significant decreases(threshold p < 0.01) in uptake
were detected and are summarized in Fig. 2a as the
Fig. 1 In vivo μPET quantification of (a) [18F]FDG, (b) [11C]PiB, and (c)
[18F]AV45 uptake in WT and APPPS1-21 mice using VOI analysis. Data
are expressed as mean + standard deviation, unpaired Student t-test
**** p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 (Holm-Sidak correction
for multiple comparisons). μPET micro-positron emission tomography,
FDG fluorodeoxyglucose, PiB Pittsburgh compound B, WT wild type, VOI
volume of interest
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percent of significantly changed voxels within each brain
region. The thalamus was the most affected with near
widespread significant reductions (96.96 %, maxT = 3.35)
and was followed by the striatum in which significant de-
creases covered more than half of the region (61.21 %,
maxT = 3.29). The hippocampus (34.22 %, maxT = 3.13),
cerebellum (32.68 %, maxT = 3.98), and brain stem
(22.66 %, maxT = 4.49) were affected to a lower extent
while the cortex (6.74 %, maxT = 3.19) and amygdala
(0.57 %, maxT = 2.64) showed minimal changes. This is vi-
sualized in Fig. 3 where the statistical T-map illustrates
these regions of significantly decreased [18F]FDG uptake
in APPPS1-21 mice compared to WT.
[11C]PiB and [18F]AV45
VOI analysis (Fig. 1b) demonstrated increased reten-
tion of [11C]PiB in APPPS1-21 mice with the cortex
(p = 8.35e-005) and hippocampus (p = 1.54e-005) showing
the greatest significant difference. [18F]AV45 retention
was increased in APPPS1-21 mice but did not reach
significance.
Additionally, [11C]PiB and [18F]AV45 uptake was simi-
larly analyzed using voxel-wise analysis and a two-sample
unpaired t-test (threshold p < 0.01, extent threshold
100 voxels). APPPS1-21 mice demonstrated a number of
regions with significantly increased [11C]PiB binding. These
increases are summarized in Fig. 2b and illustrated in Fig. 3.
The hippocampus demonstrated the most substantial
changes (87.84 %, maxT = 7.15) followed by the cortex
(69.08 %, maxT = 7.93), striatum (64.75 %, maxT = 7.05),
and thalamus (64.57 %, maxT = 5.82). Modest changes
(<15 %) were observed in the brain stem, cerebellum, and
amygdala. Using the same threshold value, significantly in-
creased [18F]AV45 uptake was also demonstrated (Fig. 2c);
however, in comparison to [11C]PiB there were notably
lower maxT values (i.e., less significance) and less wide-
spread changes. With this tracer the cortex demonstrated
the most widespread significant differences (48.01 %,
maxT = 4.68), followed by the hippocampus (32.84 %,
maxT = 3.89) and striatum (11.09 %, maxT = 3.59). Figure 3
compares the localization of significant changes for
[18F]FDG, [11C]PiB, and [18F]AV45. While amyloid binding
is predominantly in the cortex, [18F]FDG decreases are in
the mid- to hind-brain regions although some overlap can
be observed in the thalamus, striatum, and hippocampus.
Ex- vivo validation
Ex-vivo [14C]2-DG autoradiography
Figure 4a shows the quantitative analysis of [14C]2-DG
autoradiography. The corpus callosum was found to be
metabolically stable in APPPS1-21 mice and was thus
used as a reference region to normalize regional uptake
values. Multiple comparisons using unpaired Student
t-tests (with Holm-Sidak correction) were performed
for each region to assess the differences between
APPPS1-21 and WT mice. This analysis revealed that
significant decreases in [14C]2-DG uptake were found
in the thalamus (p = 0.00006), striatum (p = 0.0041),
and hippocampus (p = 0.00006).
Immunohistochemistry
Brain amyloid plaque load was determined in APPPS1-
21 mice with 4G8 immunostaining. Plaque load was
Fig. 2 In vivo analysis of glucose utilization and fibrillar amyloid-β
using voxel-wise SPM analysis. Graphs show the results from regional
voxel-wise analysis of μPET data. Statistically significant voxels relative
to the total number of voxels in a region are depicted for a [18F]FDG,
b [11C]PiB, and c [18F]AV45. ). SPM statistical parametric mapping, μPET
micro-positron emission tomography, FDG fluorodeoxyglucose, PiB
Pittsburgh compound B
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abundant in these aged mice, with amyloid deposition
highest in the frontal cortex (7.67 ± 0.71 % marker stain)
followed by the cortex at the level of the hippocampus
(4.95 ± 0.97 % marker stain), amygdala (4.12 ± 1.47) and
thalamus (3.43 ± 0.45 % marker stain). In line with its
low transgene expression, minimal plaque staining was
observed in the cerebellum (0.24 ± 0.14 % marker stain)
(Fig. 5c). No amyloid plaques were detected in WT
mice.
Genotypic differences in inflammatory markers were
investigated in the cortex, hippocampus, and thalamus
by immunohistochemistry for activated microglia and
astrocytes with Iba-1 (Fig. 6a-c) and GFAP, respectively
(Fig. 6d-f). Multiple comparisons using unpaired Student
t-tests (with Holm-Sidak correction) were performed for
each region to assess the differences between APPPS1-21
and WT mice. Both GFAP and Iba-1 staining were signifi-
cantly increased in APPPS1-21 mice in the regions investi-
gated (p < 0.0001) (Fig. 6a and d).
Correlation analysis
To investigate the relationship between the in vivo μPET
measurements and relative ex vivo gold standards in
APPPS1-21 mice we performed correlation analyses
(Pearson correlation test). The absolute quantification of
the μPET data in either %ID/g ([11C]PiB and [18F]AV45)
or %ID/gglc ([
18F]FDG) derived from VOI analysis (Fig. 1)
was employed in this analysis. We found that regional
[18F]FDG uptake values demonstrated a significant posi-
tive correlation to ex vivo [14C]2-DG measures in these
transgenic mice (r = 0.67, r2 = 0.45, p <0.0001) (Fig. 7a).
We investigated the association between regional
Fig. 3 Statistical parametric T-maps obtained from voxel-wise analysis of μPET data with [18F]FDG, [11C]PiB and [18F]AV45
Fig. 4 Ex vivo measures of glucose utilization with [14C]2-DG autoradiography in aged APPPS1-21 and WT mice. a Box-plots show the normalized
regional [14C]2-DG uptake values for WT and APPPS1-21 mice in different brain regions. Unpaired Student t-test,** p < 0.01, *** p < 0.001. Representative
images are shown for (b) a WT and (c) a APPPS1-21 animal. 2-DG 2-deoxy-D-glucose, WT wild type
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Fig. 5 Ex vivo immunohistochemistry for amyloid-β with 4G8 immunostaining in APPPS1-21 mice. a Data are presented as the max and min ± standard
deviation. Representative images from (b) the frontal cortex and (c) the cerebellum of an APPPS1-21 mouse (Scale bar = 100 μm)
Fig. 6 Ex vivo immunohistochemistry for the inflammatory markers GFAP and Iba-1 in APPPS1-21 and WT mice. a and (d) data are presented as
the max and min ± standard deviation. Unpaired Student t-test **** p < 0.0001. Representative images from the cortex of WT (b) and (e), and
APPPS1-21 c and f mice (Scale bar = 50 μm). GFAP glial fibrillary acidic protein, Iba-1 ionized calcium-binding adaptor molecule 1, WT wild type
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[18F]FDG uptake and amyloid-β deposition but found
that these measures were not correlated (r = 0.01, r2 = 2e
−006, p = 0.99) (Fig. 7b). In contrast, in vivo [11C]PiB and
[18F]AV45 binding did not correlate strongly to ex vivo
4G8 immunostaining for amyloid-β in APPPS1-21 mice
(r = 0.25, r2 = 0.06, p = 0.07 and r = 0.17, r2 = 0.03, p = 0.26
respectively) (Fig. 7c and d).
Discussion
Due to its non-invasive nature, μPET imaging is an at-
tractive modality for preclinical investigation that allows
for the visualization of multiple neuropathological bio-
markers. [18F]FDG detected significant decreases in
cerebral metabolism in APPPS1-21 mice and showed a
high congruency to ex vivo measures of [14C]2-DG. Both
[11C]PiB and [18F]AV45 demonstrated significant uptake
in APPPS1-21 mice but showed poor sensitivity when
compared to ex vivo amyloid quantification. The de-
tected reductions in [18F]FDG did not correlate to re-
gions of highest amyloid-β burden.
A number of animal models of AD have been investi-
gated with in vivo [18F]FDG imaging but no consensus
has been reached on its utility. On the whole, most in-
vestigations of amyloidosis-only models have revealed
unchanged [24, 25] or increased uptake [26–28], counter
to the clinical phenotype. These findings were inter-
preted as a fundamental limitation of animal models
and, additionally, a limit in the sensitivity of μPET. How-
ever, more recently, widespread significant decreases in
[18F]FDG in the 5 x FAD model have been reported [31]
and we have detected significant regional decreases in
the double transgenic TASTPM model [32, 33]. It is pos-
sible that normal, hypometabolism and hypermetabolism
can be observed at different disease stages in animal
models depending on disease severity that depends on
both the mutations and the age at imaging. Other likely
contributors to the controversy are methodological dif-
ferences, especially in relation to analysis. Normalization
of regional uptake values to a reference region is common
but may yield inaccurate results if such regions are com-
promised by disease [45]. In comparison the use of voxel-
wise analysis provides more sensitivity to detect changes
and allows for multiple hypothesis testing (i.e., hyper or
hypo) and should thus be routinely implemented in stud-
ies of cerebral glucose metabolism One limitation of μPET
imaging is the necessitation to anesthetize the animal and
in the case of [18F]FDG studies this results in substantially
reduced brain uptake of the tracer [46]. The [14C]2-DG
protocol is, however, performed without the confounding
effects of anesthesia and, thus, the correlation between in
vivo and ex vivo results strongly suggests that the
[18F]FDG findings are reliable. With the aforementioned
methodological considerations we have now demonstrated
[18F]FDG reductions in two transgenic models of AD and
aim to further extend our findings in other models for
multiple stages of pathology.
While this is the first investigation of cerebral glucose
utilization in the APPPS1-21 model, these mice have been
previously characterized with amyloid imaging [15, 16, 38].
Significant differences between WT and APPPS1-21
mice in the cortex have been detected at five months
with [18F]AV45 [16] and at 8.4 months with [11C]PiB
Fig. 7 Correlation analyses between in vivo μPET data and ex vivo measures of amyloid burden and glucose utilization. a Graph depicting
[18F]FDG and [14C]2-DG quantification of brain glucose utilization. b Graph of [18F]FDG uptake versus amyloid burden. c Graph of [11C]PiB and
4G8 quantification of amyloid burden. d Graph of [18F]AV45 and 4G8 quantification of amyloid burden. Each dot represents a regional value from
an individual animal (cortex, striatum, amygdala, hippocampus, thalamus, and cerebellum). Only APPPS1-21 mice were included in this analysis.
μPET micro-positron emission tomography, FDG fluorodeoxyglucose, 2-DG 2-deoxy-D-glucose, PiB Pittsburgh compound B
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[15]. In this study, both [11C]PiB and [18F]AV45 demon-
strated increased retention in APPPS1-21 mice with
[11C]PiB showing a higher discriminative power. [11C]PiB
has previously been shown to have a greater dynamic
range than most fluorinated alternatives [38, 47]. The re-
duced contrast obtained with tracers, such as [18F]AV45
and [18F]florbetaben, is due to a higher proportion of non-
specific binding resulting from a combination of white
matter retention and the uptake of brain penetrant radio-
metabolites. With relevance to the current findings, Choi
et al. described two main brain penetrant radiometabolites
of [18F]AV45 [48]. The non-specific uptake of these me-
tabolites most likely accounts for the poor performance of
[18F]AV45 when compared to [11C]PiB. A previous pre-
clinical study found a similarly low contrast whereby only
a 14.5 % difference between WT and transgenic mice
(5XFAD) was observed with [18F]-AV45 in comparison to
a 21 % difference obtained with [11C]-PiB in the same
mouse cohort [27]. While we detected amyloid-β in vivo
with [11C]PiB and [18F]AV45 binding, we observed dis-
crepancies with ex vivo determinants of amyloid-β load
for both these tracers. Voxel-wise analysis of [11C]PiB
binding found the hippocampus to have the most wide-
spread increases whereas immunohistochemistry showed
this region had lower amyloid-β deposition than in the
thalamus, cortex, and striatum. We have previously de-
scribed poor correlation between in vivo binding of amyl-
oid tracers and ex vivo measures of amyloid with
[18F]AV45 [33], [18F]florbetaben, and [11C]PiB [38]. The
accuracy of in vivo detection could be improved by partial
volume corrections [49] but the poor correlation is also
indicative of the high non-specific binding inherent to
these amyloid tracers.
Although aged APPPS1-21 mice demonstrated signifi-
cant reductions in cerebral metabolism, the regions af-
fected were not congruent with those of human AD. In
AD, patients typically show reduced [18F]FDG uptake in
the precuneus, posterior cingulate, and temporal and
parietal cortex. With increasing disease severity hypome-
tabolism spreads to frontal association cortices but me-
tabolism remains largely preserved in the striatum,
thalamus, visual and sensorimotor cortices, and the cere-
bellum and brain stem throughout disease progression
[2]. In aged APPPS1-21 mice, minimal reductions were
observed in the cortex whereas the most significant re-
ductions were in the thalamus and striatum. Moreover,
typically amyloid-free regions in these mice, such as the
brain stem and cerebellum, also demonstrated significant
reductions. While some previous ex vivo autoradiog-
raphy studies with [18F]FDG and [14C]2-DG found sig-
nificant decreases in AD relevant structures, such as the
retrospinal and/or cingulate cortex [19, 20], the overall
pattern of [18F]FDG/[14C]2-DG was incongruent to hu-
man AD. These incongruences are perhaps not surprising
given the inherent differences between animal models and
human AD. The majority of cerebral amyloidosis models
do not develop overt neuronal death [9] which is a prom-
inent hallmark of human AD and is thought to largely
underlie decreases in [18F]FDG uptake. While amyloid de-
position initiates at six to eight weeks of age, only modest
neuronal loss is observed beginning at eight months in
APPPS1-21 mice [36]. Accordingly, these animals showed
no brain atrophy when investigated with MRI voxel-based
analysis [50]. The neuronal loss that was observed was
found in the dentate gyrus and CA1 layers of the hippo-
campus [36, 51]. Atrophy and neuronal loss were not-
ably absent in the cortex which could explain the lack of
[18F]FDG decreases in this region [50, 51]. Further in-
vestigations into the biological underpinnings of
[18F]FDG decreases in this model are required. Of inter-
est, early loss of dendritic spines has been reported in
APPPS1-21 mice and could thus represent a relevant
target for future studies [34].
Despite some overlapping pathology, decreases in
[18F]FDG uptake do not correlate well with increases in
amyloid retention [52, 53]. Inflammation in high plaque-
bearing regions has been postulated as a factor for the
lack of correlation between amyloid tracer retention and
reductions in [18F]FDG [54]. As glial cells also use glu-
cose as an energy source it is proposed that increased in-
flammation in proximity to plaques may mask decreased
neuronal activity. Indeed, in a study of aged monkeys
[18F]FDG uptake positively correlated with increased
binding of the microglial marker [11C]DPA-713 rather
than with [11C]PiB binding [54]. In APPPS1-21 mice, ac-
tivated microglia and astrocytes appear in tandem with
the onset of amyloid deposition and increase in number
with disease progression [36]. In line with these observa-
tions, we demonstrated significant increases in inflamma-
tory markers for astrocytes (GFAP) and microglia (Iba-1)
in the thalamus, cortex and hippocampus of APPPS1-21
mice. Despite this robust neuroinflammation, APPPS1-21
mice still demonstrate significant [18F]FDG decreases.
While this does not discount the involvement of inflam-
mation in the [18F]FDG signal, taken together we find it
insufficient to fully account for the poor correlation. An
alternative hypothesis for this dissociation is network de-
generation which proposes that the disease propagates
along neuronal networks [55]. In this case amyloid depos-
ition in addition to causing local synaptic dysfunction
would also induce dysfunction in functionally connected
regions which may themselves be amyloid-free. This the-
ory is supported by recent clinical evidence demonstrating
that worsening amyloidosis is correlated to worsening
hypometabolism in both local and functionally related re-
gions [56]. It should, however, be remembered that im-
aging data relates to measures of fibrillar amyloid-β and
thus does not provide information on the relationship
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between soluble amyloid-β which is especially neurotoxic
and likely influences neuronal dysfunction [57]. Interest-
ingly, decreases in functional connectivity have been re-
ported in APPPS1-21 mice with resting state fMRI [58].
We only investigated pathology in our animal model
at a single time point. Additionally we choose this old
age time point as we expected substantial pathological
burden at this stage of disease. Therefore, to fully assess
the utility of [18F]FDG and to delineate the temporal re-
lationship between amyloid deposition and neuronal
dysfunction a longitudinal study should be performed.
Furthermore, in this study we aimed to primarily demon-
strate [18F]FDG as a useful tracer in preclinical investiga-
tions. Future investigations should focus on finding the
underlying mechanisms of these [18F]FDG alterations and
their relationship to neurodegeneration as has been re-
cently described in a Tau transgenic model [59].
Conclusions
Our study provides support for the use of [18F]FDG as
an in vivo technique to investigate abnormal cerebral
glucose utilization in transgenic models of AD. Our find-
ings suggest that the combined use of in vivo amyloid and
[18F]FDG μPET imaging will aid in understanding the re-
lationship between amyloid and neuronal dysfunction.
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